Levopraid (Levosulpiride)

Levosulpiride works by selectively blocking dopamine D2 receptors in the brain, which reduces psychotic symptoms. In the gastrointestinal system, this blockade increases acetylcholine release, stimulating smooth‑muscle activity and promoting faster gastric emptying.

The dosage of Levopraid is individualized by the prescribing clinician based on the patient’s condition, severity, and response. The prescriber determines the appropriate strength, frequency, and duration of therapy.

Safety data for levosulpiride in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Levopraid product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Levopraid (levosulpiride) is a benzamide antipsychotic that primarily blocks D2 receptors with additional pro‑kinetic effects, distinguishing it from many atypical antipsychotics that have broader receptor profiles. Its dual psychiatric and gastro‑pro‑kinetic activity can be advantageous in patients with co‑existing digestive symptoms.

Levopraid tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. No refrigeration is required.

Levopraid is taken orally, usually with or without food, as directed by the prescribing physician. The tablets are swallowed whole with a glass of water.

Serious risks include extrapyramidal symptoms such as dystonia or akathisia, hyperprolactinemia, severe allergic reactions, cardiac arrhythmias, and the rare but life‑threatening neuroleptic malignant syndrome. Patients should be monitored closely for these events.

Levopraid is contraindicated in patients with known hypersensitivity to levosulpiride or any component of the formulation, and it should be used with caution in individuals with severe hepatic impairment, uncontrolled cardiac disease, or a history of neuroleptic malignant syndrome.